Tomohiro Osaki

Tomohiro Osaki

Auto-generated profile, based on publicly available information

Tomohiro Osaki

Department of Surgery, Tottori Prefectural Central Hospital, Tottori, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TOTomohiro Osaki
Tomohiro Osaki
HSHiroaki Saito
Hiroaki Saito
SSShota Shimizu
Shota Shimizu
YMYuki Murakami
Yuki Murakami
KMKozo Miyatani
Kozo Miyatani
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara

30 September 2023 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TOTomohiro Osaki
Tomohiro Osaki
STShigeru Tatebe
Shigeru Tatebe
JOJunpei Orihara
Junpei Orihara
EUEi Uchinaka
Ei Uchinaka
KAKeigo Ashida
Keigo Ashida
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara

1 January 2019 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
MIMasahide Ikeguchi
Masahide Ikeguchi
KGKeisuke Goto
Keisuke Goto
JWJune Watanabe
June Watanabe
SUShoichi Urushibara
Shoichi Urushibara
TOTomohiro Osaki
Tomohiro Osaki
SNSeiichi Nakamura
Seiichi Nakamura
Ikeguchi M, et al. Ann Hepatobiliary Pancreat Surg. 2019 Nov;23(4):372-376. https://doi.org/10.14701/ahbps.2019.23.4.372

21 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
NINanami Irie
Nanami Irie
KMKana Mizoguchi
Kana Mizoguchi
TWTomoko Warita
Tomoko Warita
MNMirai Nakano
Mirai Nakano
KSKasuga Sasaki
Kasuga Sasaki
KWKatsuhiko Warita
Katsuhiko Warita
Metastatic melanoma has a very poor prognosis. Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors, are cholesterol-lowering agents with a potential for cancer treatment. The inhibition of HMGCR by statins, however, induces feedback, which paradoxically upregulates HMGCR expression via sterol regulatory element-binding protein-2 (SREBP2). Dipyridamole, an antiplatelet agent, is known to inhibit SREBP2 upregulation. We aimed to demonstrate the efficacy of statin–dipyridamole combination treatment in both human and spontaneously occurring canine melanoma cell lines. The half maximal inhibitory concentration (IC50) of atorvastatin showed a 68–92% reduction when combined with dipyridamole, compared with that of atorvastatin alone. In some melanoma cell lines, cell proliferation was suppressed to almost zero by the combination treatment (≥3 μM atorvastatin). Finally, the BRAF inhibitor, vemurafenib, further potentiated the effects of the combined statin–dipyridamole treatment in BRAF V600E mutation-bearing human melanoma cell lines. In conclusion, the inexpensive and frequently prescribed statin–dipyridamole combination therapy may lead to new developments in the treatment of melanoma and may potentiate the effects of vemurafenib for the targeted therapy of BRAF V600E-mutation bearing melanoma patients. The concordance between the data from canine and human melanoma cell lines reinforces this possibility.

14 December 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
TOTomohiro Osaki
Tomohiro Osaki
TMTomoyuki Matsunaga
Tomoyuki Matsunaga
MMMasahiro Makinoya
Masahiro Makinoya
YSYuji Shishido
Yuji Shishido
KMKozo Miyatani
Kozo Miyatani
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara

12 December 2024 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
TOTomohiro Osaki
Tomohiro Osaki
TMTomoyuki Matsunaga
Tomoyuki Matsunaga
MMMasahiro Makinoya
Masahiro Makinoya
SSShota Shimizu
Shota Shimizu
YSYuji Shishido
Yuji Shishido
YFYoshiyuki Fujiwara
Yoshiyuki Fujiwara